News
Media
Conferences
CME/CE
Partners
Publications
Resources
Subscribe

Bianca Weinstock-Guttman, MD

Articles by Bianca Weinstock-Guttman, MD

Impact of Results From the COVID-19 in MS Global Data-Sharing Initiative

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

CLARITY Extension Trial: Disability Improvement With Cladribine

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Chief Endpoints and Potential Significance: Phase 3b OLIKOS Trial

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Ofatumumab vs Teriflunomide: Phase 3 ASCLEPIOS I/II Open-Label Extension Study

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Key Takeaways from the 8th ACTRIMS-ECTRIMS 2020 Meeting

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Ozanimod Compared to Teriflunomide Utilizing Statistical Matching

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

OLKIOS Phase 3b Trial: Pivotal Endpoints and Potential Significance

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Phase 3 ASCLEPIOS I/II Open-Label Extension Study: Ofatumumab vs Teriflunomide

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Takeaways From ACTRIMS-ECTRIMS 2020 Meeting

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Rationale for Selected Dosing Regimen of Evobrutinib in Phase 3 Studies

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

OLKIOS: Looking at Ofatumumab’s Continued Efficacy

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Ofatumumab vs Teriflunomide: ASCLEPIOS I/II RMS Trials

ByMark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC,Robert Naismith, MD,Bianca Weinstock-Guttman, MD

November 24th 2020

Latest Updated Articles

CLARITY Extension Trial: Disability Improvement With Cladribine
Published: November 24th 2020 | Updated:
OPTIMUM Phase 3 Trial: Ponesimod’s Cardiac Safety Data
Published: November 24th 2020 | Updated:
COVID-19 in MS Global Data-Sharing Initiative Anti-CD20 Therapy Results
Published: November 24th 2020 | Updated:
Takeaways From ACTRIMS-ECTRIMS 2020 Meeting
Published: November 24th 2020 | Updated:
OLKIOS: Looking at Ofatumumab’s Continued Efficacy
Published: November 24th 2020 | Updated:
OPTIMUM: Ponesimod Superiority in MRI-based Outcomes in RRMS
Published: November 24th 2020 | Updated:

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Low-Dose Opioids Show Long-Term Dose Stability, Effectiveness in Augmented Restless Legs Syndrome

FDA Requests HOPE-3 Clinical Study Report for Deramiocel BLA in DMD Cardiomyopathy

Levacetylleucine Meets Primary and Secondary End Points in Phase 3 Ataxia-Telangiectasia Study

Enhancing Biomarker Use and Targeted Treatment Approaches in Alzheimer Disease: Aaron Burstein, PharmD

NLX-112 Shows Safety and Tolerability in Phase 2a Parkinson Trial, Supporting Further Development